Compare ORC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORC | OMER |
|---|---|---|
| Founded | 2010 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2011 | 2008 |
| Metric | ORC | OMER |
|---|---|---|
| Price | $4.79 | $18.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $27.50 |
| AVG Volume (30 Days) | ★ 6.7M | 1.0M |
| Earning Date | 10-22-2026 | 11-12-2026 |
| Dividend Yield | ★ 23.86% | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $32.05 | N/A |
| Revenue Next Year | N/A | $73.59 |
| P/E Ratio | ★ N/A | $24.20 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.75 | $6.24 |
| 52 Week High | $8.40 | $21.24 |
| Indicator | ORC | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 30.42 | 52.83 |
| Support Level | N/A | $18.01 |
| Resistance Level | $5.28 | $19.81 |
| Average True Range (ATR) | 0.18 | 0.91 |
| MACD | 0.04 | 0.10 |
| Stochastic Oscillator | 8.49 | 63.02 |
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.